Irvine, California, USA — July 27, 2026
July 27, 2026 – AnHorn Medicines has announced the successful first subject first dose in the Phase I clinical trial of AH-008, a first-in-class neuroprotective drug candidate being developed to prevent chemotherapy-induced peripheral neuropathy (CIPN). The milestone marks the clinical advancement of a novel preventive therapy designed to address one of the most common and debilitating side effects of cancer treatment. The Phase I study will evaluate the safety, tolerability, and pharmacokinetics of AH-008 in healthy volunteers, providing the foundation for future clinical development in cancer patients at risk of developing CIPN. With no approved therapies currently available to prevent CIPN, the company believes AH-008 has the potential to transform supportive oncology by protecting patients from chemotherapy-related nerve damage while helping maintain optimal cancer treatment.
AH-008 Targets a Major Unmet Need in Supportive Oncology
Chemotherapy-induced peripheral neuropathy (CIPN) is a common dose-limiting toxicity associated with widely used cancer therapies, including taxanes, platinum-based chemotherapy, vinca alkaloids, and antibody-drug conjugates (ADCs). The condition can cause persistent numbness, tingling, pain, and sensory impairment, significantly reducing patients’ quality of life and often forcing oncologists to reduce chemotherapy doses, delay treatment schedules, or discontinue therapy altogether. According to AnHorn Medicines, approximately 60% to 70% of patients experience CIPN during or shortly after chemotherapy, while nearly one-third continue to experience symptoms for six months or longer. AH-008 is designed to prevent nerve damage before irreversible neuropathy develops through a first-in-class mechanism targeting chemotherapy-induced neuroinflammation, offering a preventive strategy rather than treating symptoms after they occur.
Phase I Study Supports Future Development in Cancer Patients
The ongoing Phase I clinical trial is evaluating AH-008 in healthy volunteers to establish its safety profile, tolerability, and pharmacokinetic characteristics before advancing into studies involving cancer patients receiving neurotoxic chemotherapy. Chief Scientific Officer Shu-Jen Chen highlighted that preventing CIPN represents one of the largest unmet needs in supportive cancer care, noting that the condition carries an estimated economic burden of approximately $17,000 per patient and contributes to a broader societal cost of up to $153 billion. By preventing chemotherapy-induced nerve injury, AH-008 has the potential to improve patient quality of life, reduce chronic neurological complications, preserve chemotherapy dose intensity, and enable patients to remain on potentially life-saving cancer treatments without compromising therapeutic effectiveness.
Advertisement
AI-Driven Drug Discovery Supports Commercial Potential
Founded in 2020, AnHorn Medicines is an AI-driven biotechnology company focused on developing small-molecule therapeutics and protein degraders across oncology, supportive cancer care, and aesthetic medicine. The company utilizes its proprietary AIMCADD artificial intelligence platform, combining generative AI with molecular simulation to accelerate drug discovery and optimize novel therapeutic candidates. With an estimated global market opportunity of $15 billion to $19 billion annually for CIPN prevention, AH-008 represents a significant commercial opportunity as the first potential preventive therapy in this space. AnHorn believes the treatment could establish a new standard in supportive oncology, similar to how granulocyte colony-stimulating factors (G-CSFs) transformed the management of chemotherapy-induced neutropenia by enabling patients to receive full-dose cancer treatment.
Source: AnHorn Medicines press release
